Share on StockTwits

Shares of Protalix BioTherapeutics (NYSE:PLX) were the recipient of a significant decline in short interest in May. As of May 15th, there was short interest totalling 6,041,735 shares, a decline of 1.0% from the April 30th total of 6,105,080 shares, Analyst Ratings Network reports. Approximately 8.3% of the company’s stock are sold short. Based on an average daily volume of 176,663 shares, the short-interest ratio is presently 34.2 days.

Several analysts have recently commented on the stock. Analysts at JPMorgan Chase & Co. cut their price target on shares of Protalix BioTherapeutics from $8.00 to $7.00 in a research note on Tuesday, May 13th. They now have an “overweight” rating on the stock. Separately, analysts at Jefferies Group reiterated a “hold” rating on shares of Protalix BioTherapeutics in a research note on Monday, May 12th. They now have a $4.25 price target on the stock, down previously from $5.50. Finally, analysts at Zacks downgraded shares of Protalix BioTherapeutics from a “neutral” rating to an “underperform” rating in a research note on Wednesday, April 9th. They now have a $4.30 price target on the stock.

Protalix BioTherapeutics (NYSE:PLX) opened at 3.96 on Thursday. Protalix BioTherapeutics has a 52 week low of $3.70 and a 52 week high of $5.72. The stock has a 50-day moving average of $4.04 and a 200-day moving average of $4.34. The company’s market cap is $367.0 million.

Protalix BioTherapeutics (NYSE:PLX) last issued its quarterly earnings data on Thursday, May 22nd. The company reported ($0.08) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.07) by $0.01. On average, analysts predict that Protalix BioTherapeutics will post $-0.19 earnings per share for the current fiscal year.

Protalix BioTherapeutics, Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its ProCellEx protein expression system, ProCellEx.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.